2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Cancer Drugs Market
The sales of cancer drugs and related services by entities (organizations, sole traders, and partnerships) that create oncology drugs to diagnose and treat all forms of malignancies constituting the oncology drugs market. This industry comprises manufactures of medications for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain cancer, and other cancers with chemotherapy, surgery, and radiotherapy. Drugs are developed by the pharmaceutical industry to diagnose, cure, or prevent diseases. Since 2015, the worldwide oncology drugs market has grown at a compound annual growth rate (CAGR) of 9.8%, reaching over $167.9 billion in 2019. At a CAGR of 9.7%, the market is predicted to rise modestly from $201.1 billion in 2021 to $284.5 billion in 2023. The market is predicted to level out in 2025, reaching $284.5 billion and $412.9 billion by 2030.
- Strong pipeline of drugs
- Drug market: current and expected trends
- Oncology market during pandemic
- FDA rules and regulations
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China